BioPharmSignal logoBioPharmSignal

Biotech News

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

Arcutis Biotherapeutics (ARQT)Arcutis BiotherapeuticsClinical readout

Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT program ZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months over four

Related news

ARQTArcutis Biotherapeutics2026-03-18 12:00 EST

Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting

ARQTArcutis Biotherapeutics2026-04-22 12:00 EST

Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

View all latest news

Arcutis Biotherapeutics

Medical Dermatology Arcutis Biotherapeutics develops and commercializes targeted therapies for immune-mediated skin diseases, emphasizing convenient topical formulations against validated biology. ZORYVE Franchise ZORYVE is a once-daily topical roflumilast product available in cream and foam formulations across plaque psoriasis, atopic...

Recent company news

ARQTArcutis Biotherapeutics2026-08-07 20:00 EST

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQTArcutis Biotherapeutics2026-08-05 20:00 EST

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

ARQTArcutis Biotherapeutics2026-07-16 13:00 EST

Arcutis Expands Board of Directors with Appointment of Chris Peetz

ARQTArcutis Biotherapeutics2026-07-15 20:00 EST

Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

ARQTArcutis Biotherapeutics2026-07-08 12:00 EST

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

Stock data

Close
25.08 USD
Market cap
2.6B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States